The share price of Genedrive (AIM: GDR) rose by 20 percent at the opening of the markets following announcement that it is making tangible moves in the USA.
Near patient molecular diagnostics company genedrive revealed that the first shipments to the USA of its Genedrive 96 SARS-CoV-2 Kits has started.
These shipments follow a previous announcement regarding its distribution agreement with Beckman Coulter Life Science. Alongside the shipping of the kits to the USA, GDR has also completed commercial and technical training with sales representatives at Beckman Coulter.
Beckman Coulter can now start preparing to sell and roll-out the supplied kits to the wider market.
Commenting on the shipments was CEO David Budd:
“This is an important milestone for genedrive as the first shipments of our Genedrive 96 SAR-CoV-2 kit are exported to the US. We are very optimistic about the US market for Covid PCR testing and it has market drivers that are favorable to the adoption of the genedrive assay: efficiency, ease of use, automation friendly, and scalability.”
The share price of GDR is currently trading at 152p.